Data as of Dec 19
| +0.70 / +0.60%|
Celgene Corp. engages in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. It is dedicated to innovative research and development, which is designed to bring new therapies to market and is involved in research in several scientific areas such as immunomodulation and intracellular signaling pathways in hematology, oncology and immune-inflammatory diseases. Its portfolio of commercial products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
|Robert J. Hugin||Chairman & Chief Executive Officer|
|Mark J. Alles||President & Chief Operating Officer|
|Peter N. Kellogg||Chief Financial Officer & Executive Vice President|
|Jerome Bernard Zeldis||Chief Medical Officer & CEO-Global Health|
|Thomas O. Daniel||EVP, President-Research & Early Development|